Global Thalassemia Market 2020 Global Share, Trend, Segmentation And Forecast To 2026|Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio

Global Thalassemia Market is expected to rise from its initial estimated value of USD 1.99 billion to a projected value of USD 4.36 billion by 2026, registering a CAGR of 10.29% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing concern and awareness regarding the disease globally.

The Thalassemia business report comprises of primary, secondary and advanced information about the global market with respect to status, trends, size, share, growth, and segments in the forecasted period of 2020 - 2026. Systemic gathering of company profiles that are driving the market is also performed in this report. This market report also measures the existing development trends and patterns along with distribution and marketing channels. The report exhibits important product developments and tracks recent acquisitions, mergers and research in the ABC industry by the key players. The Thalassemia report puts light on the entire market trends and analyses the effect of buyers, consumers, substitutes, new entrants, competitors, and suppliers on the market.

Get Sample Copy Of This Report + All Related Graphs @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-thalassemia-market

Few of the major competitors currently working in the thalassemia market are ApoPharma Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc.; Acceleron Pharma, Inc.; Incyte Corporation; Kiadis Pharma; Gamida Cell; CELGENE CORPORATION; GlaxoSmithKline plc; Ionis Pharmaceuticals, Inc.; Vifor Pharma; La Jolla Pharmaceutical Company; Lonza and Sangamo Therapeutics.

Key Developments in the Market:

In April 2019, CELGENE CORPORATION and Acceleron Pharma, Inc. announced that CELGENE had submitted a Biologics License Application (BLA) for “luspatercept” with the U.S. F.D.A. (United States Food & Drug Administration). This will help in faster commercialization and development of drugs for patients suffering from blood diseases.
In January 2019, Vifor Pharma announced positive results from their phase-I trial of “VIT-2763” an oral ferroportin inhibitor. The drug being developed for transportation of iron from one cell to another has shown signs in reduction of serum iron in a dose-dependent state.

Segmentation: Global Thalassemia Market

By Thalassemia Type

Alpha Thalassemia
Beta Thalassemia
By Therapeutic Class
Iron Chelating Drugs
Exjade/Jadenu (deferasirox)

By Pipeline

Gene Therapy
LentiGlobin

By End-User

Hospitals
Clinics
Research Institutes
Laboratories

By Geography

North America
South America
Europe
Asia-Pacific
Middle East & Africa

Market Drivers

Increasing prevalence of the disease globally without any viable treatment options available for curing the disease; this factor is expected to drive the market growth
Growth in development of pipeline drugs and development of new therapies because of R&D activities and investments by the various authorities; this factor is expected to drive the market growth

Market Restraint

Lack of viable treatment options commercialized for the treatment of disease/disorder rather than the symptoms associated with the disease; this factor is expected to restrain the market growth
High cost of treatment for the disorder is expected to act as a restraint to the market growth

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-thalassemia-market

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.